CODEX+ CELIDA Recommendations
1.5.2 - ci-build
CODEX+ CELIDA Recommendations
1.5.2 - ci-build
CODEX+ CELIDA Recommendations - Local Development build (v1.5.2) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Active as of 2022-02 |
<PlanDefinition xmlns="http://hl7.org/fhir">
<id value="TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan"/>
<meta>
<profile
value="https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/recommendation-plan"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: PlanDefinition TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan</b></p><a name="TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan"> </a><a name="hcTherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan"> </a><a name="TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan-en-US"> </a><p><b>url</b>: <a href="PlanDefinition-TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan.html">PlanDefinition Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</a></p><p><b>version</b>: 7.0</p><p><b>name</b>: Therapeutic_Anticoagulation_No_Renal_Function_Impairment</p><p><b>title</b>: Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/plan-definition-type eca-rule}">ECA Rule</span></p><p><b>status</b>: Active</p><p><b>experimental</b>: true</p><p><b>subject</b>: <a href="EvidenceVariable-PopHospitalisedNonICUCOVID19PatientsWITHHighRisk.html">Population: Hospitalised COVID-19 patients without the need for intensive care therapy considered high-risk for developing venous thrombosis</a></p><p><b>date</b>: 2022-02</p><p><b>publisher</b>: NUM CODEX+ CELIDA</p><p><b>description</b>: </p><div><p>In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered.</p>
</div><blockquote><p><b>goal</b></p><blockquote><p><b>id</b></p>aPTT-goal</blockquote><p><b>category</b>: <span title="Codes:{http://snomed.info/sct 410394004}">Lab findings surveillance (regime/therapy)</span></p><p><b>description</b>: <span title="Codes:">aPTT value should be > 50 sec.</span></p><h3>Targets</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Measure</b></td><td><b>Detail[x]</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://loinc.org 3173-2}">aPTT in Blood by Coagulation assay</span></td><td>50.0000001-? sec</td></tr></table></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>goalId</b>: aPTT-goal</p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationUFH.html">Therapeutic Anticoagulation Treatment UFH</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationNMHDalteparin1xd.html">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationNMHDalteparin2xd.html">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationNMHDalteparinTable.html">Therapeutic Anticoagulation Treatment with Dalteparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationNMHNadroparin.html">Therapeutic Anticoagulation Treatment with Nadroparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationNMHEnoxaparin1xd.html">Therapeutic Anticoagulation Treatment with Enoxaparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationNMHEnoxaparin2xd.html">Therapeutic Anticoagulation Treatment with Enoxaparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationNMHCertoparin.html">Therapeutic Anticoagulation Treatment with Certoparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationFondaparinux.html">Therapeutic Anticoagulation Treatment with Fondaparinux</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>goalId</b>: aPTT-goal</p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationWArgatra.html">Therapeutic Anticoagulation Treatment with Argatroban</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 432102000}">Administration of substance (procedure)</span></p><p><b>definition</b>: <a href="ActivityDefinition-TherapeuticAnticoagulationNMHTinzaparin.html">Therapeutic Anticoagulation Treatment with Tinzaparin</a></p></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability">
<valueCode value="computable"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel">
<valueCode value="structured"/>
</extension>
<extension url="http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-partOf">
<valueCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommendation/therapeutic-anticoagulation"/>
</extension>
<extension
url="https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/ext-action-combination-method">
<extension url="method">
<valueCodeableConcept>
<coding>
<system
value="https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-action-combination-method"/>
<code value="at-least"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="threshold">
<valuePositiveInt value="1"/>
</extension>
</extension>
<url
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/intervention-plan/therapeutic-anticoagulation"/>
<version value="7.0"/>
<name value="Therapeutic_Anticoagulation_No_Renal_Function_Impairment"/>
<title
value="Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/>
<code value="eca-rule"/>
</coding>
</type>
<status value="active"/>
<experimental value="true"/>
<subjectCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/population/hospitalised-non-icu-covid19-patients-high-risk"/>
<date value="2022-02"/>
<publisher value="NUM CODEX+ CELIDA"/>
<description
value="In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered."/>
<goal id="aPTT-goal">
<category>
<coding>
<system value="http://snomed.info/sct"/>
<code value="410394004"/>
<display value="Lab findings surveillance (regime/therapy)"/>
</coding>
</category>
<description>
<text value="aPTT value should be > 50 sec."/>
</description>
<target>
<measure>
<coding>
<system value="http://loinc.org"/>
<code value="3173-2"/>
<display value="aPTT in Blood by Coagulation assay"/>
</coding>
</measure>
<detailRange>
<low>
<value value="50.0000001"/>
<unit value="sec"/>
<system value="http://unitsofmeasure.org"/>
<code value="s"/>
</low>
</detailRange>
</target>
</goal>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<goalId value="aPTT-goal"/>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-UFH-administration"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-1xd"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-2xd"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration-table"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-nadroparin-administration"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-enoxaparin-administration-1xd"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-enoxaparin-administration-2xd"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-certoparin-administration"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-fondaparinux-administration"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<goalId value="aPTT-goal"/>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-argatroban-administration"/>
</action>
<action>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="432102000"/>
<display value="Administration of substance (procedure)"/>
</coding>
</code>
<definitionCanonical
value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-tinzaparin-administration"/>
</action>
</PlanDefinition>
IG © 2021+ Universitätsmedizin Greifswald. Package recommendations.celida.codex.netzwerk-universitaetsmedizin.de#1.5.2 based on FHIR 5.0.0. Generated 2024-08-07
Links: Table of Contents |
QA Report |
Issues |
Submit an issue |
Version History |
|